Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M14D1 and Atezolizumab in First-Line Extensive-Stage Small Cell Lung Cancer
NCT07625644Phase 3Recruiting
- Sponsor
- SystImmune Inc.
- Start
- Aug 2026
- Primary completion
- Jan 2030
- Countries
- 14
01
Overview
A Phase 3 trial of BL-M14D1 in small cell lung cancer (SCLC), sponsored by SystImmune Inc.. Started Aug 2026; status: recruiting.
02
Drugs
BL-M14D1
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07625644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07625644.